Dual Regulator (DIA-39-C20): GLP-1/GIP Dual Incretin Agonist Research Profile
DIA-39-C20 is a 39-amino acid dual GIP/GLP-1 receptor agonist with a C20 fatty diacid chain. Synergistic dual incretin activation produces greater appetite suppression and fat oxidation than single agonism alone — structurally analogous in class to tirzepatide. Full research profile and literature review.
What is DIA-39-C20?
DIA-39-C20 — branded as the Dual Regulator — is a synthetic 39-amino acid peptide engineered to co-activate both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. The C20 fatty diacid chain conjugation extends plasma half-life through albumin binding, enabling once-weekly subcutaneous dosing.
The "DIA" designation reflects its dual-agonist pharmacology. By targeting both incretin receptors — GLP-1 and GIP — DIA-39-C20 achieves mechanistic complementarity: GLP-1 receptor activation suppresses appetite and slows gastric emptying, while GIP receptor co-activation enhances insulin secretion, reduces GLP-1-related nausea, and promotes peripheral fat utilization through adipose tissue GIP receptor populations.
DIA-39-C20 is the second tier in the Regulator Series, bridging the GLP-1 monotherapy of SIA-31-C18 and the triple receptor coverage of TIA-39-C20. It is structurally analogous in pharmacological class to tirzepatide (Mounjaro/Zepbound), the FDA-approved GLP-1/GIP dual agonist.
Mechanism of action
GLP-1 receptor agonism. DIA-39-C20 activates the GLP-1 receptor in the pancreas, gut, and hypothalamus — producing glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite reduction through hypothalamic GLP-1 receptor populations. This mechanism is shared with the Single Regulator (SIA-31-C18) and forms the core of all three Regulator Series compounds.
GIP receptor co-agonism. The addition of GIP receptor activation is the defining pharmacological contribution of DIA-39-C20 over SIA-31-C18. GIP receptor agonism enhances glucose-dependent insulin secretion additively with GLP-1, reduces the gastro-intestinal side effects commonly observed with GLP-1-only compounds (nausea and vomiting), and activates GIP receptors on adipocytes — promoting fatty acid uptake regulation and fat oxidation at the peripheral tissue level. The combined GLP-1/GIP receptor activation is non-redundant and produces pharmacological synergy rather than simple addition.
C20 fatty diacid side chain. The C20 chain (arachidic diacid) provides stronger albumin binding than the C18 chain used in SIA-31-C18, further extending half-life and reducing peak-to-trough concentration variability. This contributes to smoother pharmacokinetic profiles and improved tolerability during dose escalation.
Structural specifications
| Parameter | Value |
|---|---|
| Peptide length | 39 amino acids |
| Fatty acid chain | C20 fatty diacid (arachidic diacid) |
| Receptor targets | GLP-1 receptor + GIP receptor (dual) |
| Administration | Subcutaneous injection |
| Half-life extension | Via albumin binding (C20 side chain) |
| Series position | Dual Regulator (second in the Regulator Series) |
Regulator Series comparison
| Compound | Receptor Targets | Chain Length | Fatty Acid |
|---|---|---|---|
| SIA-31-C18 (Single Regulator) | GLP-1 | 31 aa | C18 |
| DIA-39-C20 (Dual Regulator) | GLP-1 + GIP | 39 aa | C20 |
| TIA-39-C20 (Triple Regulator) | GLP-1 + GIP + Glucagon | 39 aa | C20 |
GLP-1/GIP dual agonism vs. GLP-1 monotherapy
The key research question with dual agonist compounds is what GIP receptor co-activation adds over GLP-1 alone. Clinical data from the tirzepatide development programme — the most extensively studied GLP-1/GIP dual agonist — provides important context:
- Greater weight loss: Tirzepatide 15mg achieved 22.5% mean weight loss (SURMOUNT-1) vs. approximately 15–16% for semaglutide 2.4mg (STEP-1) — a 6–7 percentage point advantage attributed substantially to GIP co-agonism.
- Improved tolerability: GIP receptor co-activation appears to reduce GLP-1-class GI side effects, particularly nausea, by counter-regulating GLP-1-induced gastric effects through distinct peripheral mechanisms.
- Fat-specific effects: GIP receptor expression on adipocytes enables dual agonists to engage peripheral fat tissue directly, not only through central appetite pathways — contributing to the superior body composition outcomes observed with dual vs. single agonists.
DIA-39-C20 provides a research-grade dual agonist tool for investigating these differential effects in controlled settings. For the broader class comparison, see our GLP-1 vs Dual Agonist vs Triple Agonist research guide.
Research dosing
The following reflects dosing parameters used in research settings. For educational purposes only — not medical advice.
| Parameter | Research Range |
|---|---|
| Dose range | 0.5–15 mg per injection |
| Frequency | Once weekly (subcutaneous) |
| Titration | Start at 0.5–2.5 mg, escalate every 4 weeks |
| Injection site | Abdomen, thigh, or upper arm (rotate sites) |
Reconstitution: Reconstitute with bacteriostatic water per vial specifications. Store reconstituted peptide refrigerated at 2–8°C. Use within 28 days of reconstitution. Do not freeze after reconstitution. Do not combine with other GLP-1 or GIP agonists.
Research sourcing: For research-grade GLP-1 class peptides with third-party COA documentation, Peptide Hub recommends Amino Club (partner code: PEPTIDEHUB). Affiliate link — we earn a commission at no cost to you.
Research references
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247. PubMed
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. PubMed
- Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled phase 2 trial. Lancet. 2023;402(10401):529–544. PubMed
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PubMed
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. PubMed
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503–515. PubMed